Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Fertinex (Serono S. A.): Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

Fertinex (Serono S. A.) - General Information

Human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the - and - subunits. The - and - subunits have 92 and 111 amino acids

 

Pharmacology of Fertinex (Serono S. A.)

Used for the treatment of female infertility, urofollitropin or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of urofollitropin is the primary hormone responsible for follicular recruitment and development.

 

Fertinex (Serono S. A.) for patients

Prior to the therapy with FertinexTM patients should be informed of the duration of treatment and monitoring of their condition that will be required. Possible adverse reactions and the risk of multiple births should also be discussed.

 

Fertinex (Serono S. A.) Interactions

No clinically significant drug/drug or drug/food interactions have been reported during FertinexTM therapy.

 

Fertinex (Serono S. A.) Contraindications

FertinexTM (urofollitropin for injection, purified) is contraindicated in women who exhibit :

1. High levels of FSH indicating primary ovarian failure.

2. Uncontrolled thyroid or adrenal dysfunction.

3. An organic intracranial lesion such as a pituitary tumor.

4. The presence of any cause of infertility other than anovulation, as stated in the "Indications" unless they are candidates for Assisted Reproductive Technologies.

5. Abnormal bleeding of undetermined origin.

6. Ovarian cysts or enlargement of undetermined origin.

7. Prior hypersensitivity to urofollitropin.

FertinexTM is also contraindicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of FertinexTM when administered during pregnancy.

 

Additional information about Fertinex (Serono S. A.)

Fertinex (Serono S. A.) Indication: For treatment of female infertility Mechanism Of Action: FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Urofollitropin Synonyms: FSH-B; FSH-beta; Follicle-stimulating hormone beta subunit; Follitropin beta chain precursor Drug Category: Fertility Agents Drug Type: Biotech; Approved Other Brand Names containing Urofollitropin: Fertinex (Serono S. A.); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Fertinex (Serono S. A.): Powder, for solution Intramuscular Chemical IUPAC Name: 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide Chemical Formula: C42H65N11O12S2 Urofollitropin on Wikipedia: https://en.wikipedia.org/wiki/Urofollitropin Organisms Affected: Humans and other mammals